All good. Everyone, I want to welcome you here. I'm Lou Basenese, MDB capital's president and chief market strategist. I have the pleasure today to be joined by Tyler Korman, the VP of research from Invizyne technologies, and Yannick Bomble, a key scientist and researcher with the National Renewable Energy Laboratory. Welcome, gentlemen. -Glad. Glad to have you here. -Thanks for having us. Glad to be here. Yeah. I appreciate you making time. We had scheduling so many different conflicts here. It's a late Friday afternoon in the summer, so I really appreciate you making time with with that consideration. So, um, before we jump into the topic of conversation today, I do just have to get some disclaimers out of the way. Uh, we are possibly going to make some forward looking statements. Um, because of that, I encourage you to read the latest SEC filings that Invizyne has placed with their registration statement to review the risks and uncertainties associated with the company, the technology, and the proposed offering of shares. So with that being said, uh, let me tell you why we're here today. Uh, we've gathered this, this group, uh, to really bridge the gap. Uh, I come from the investment world. Many like many of you. Uh, and we have two preeminent scientists with us to really talk about the technology and that how they're working together. Because in October of last year, you'll recall that Invizyne was selected to be part of a shell game changer accelerator program that is sponsored empowered by the NREL, where Yannick works. The purpose of this program is really to provide promising clean tech startups with access to financial resources, state of the art facilities and then technical experts to work with, like Yannick. And it's really focused on discovering and advancing emerging clean technologies with the potential, in their words, to dramatically alter the future global energy landscape. So big overarching purpose, a very big award for Invizyne Technologies. And we wanted to put that into perspective for investors. What does it mean? So it's my job as the resident layman to try and get these two geniuses in science to, to help us understand that. So without further ado, let me start with you. Yannick, let me ask you. It says here, if I look at your bio, that you have research interests in development of thermal bacteria, uh, the characterization, modeling of biomass and degrading enzymes, which is a bunch of gobbledygook to a guy like me. So explain to me what it is you're passionate about. What do you do? What have you been doing? And then how does -that relate to Invizyne? -So yeah, so basically we're trying to do whatever we can to power, you know, um, a new bio economy, right. And so my role and well have been there for about 15 years, um, and I have a group of about 20, 25 people historically we've worked on how do you convert biomass. So like trees and grasses and so on. How do you break them down to like basically sugars, things that microbes can take in and actually make products from. Right. So ethanol is a good example of this. So how do you break this really complex architecture of the plant cell or whatever is in the tree and so on. Get it down to those monomers, convert it and convert that at really high amounts of, of those biochemicals. Right. Um, and so historically we've done this. We still do the deconstruction of that biomass down to monomers. But we've realized that there are some, you know, issues with microbes. Um, they don't like to make certain products, um, certain feedstocks are toxic and so on. And so that's when we got interested in, in cell free catalysis. That was probably six years ago. And we started to kind of look at the landscape. Right. What are people doing? And of course, we came across those great papers from Tyler, um, with a lot of, of their early successes. Right. And that's how we kind of got interested. We had some technologies of our own to basically put enzymes on, on protein scaffolds. We thought that could be interesting. That's when we started talking to Tyler. Um, and at that point, Tyler was at UCLA. Right. And that became a collaboration at Invizyne once Invizyne came online. Okay, so it was an outreach from you and your team at the NREL to Tyler and the team over at UCLA. Yeah. So the very beginning, yes, we we were so impressed by the results they got in those papers that we wanted to reach out and talk to them. Okay. No. That's good. It's a great segue to because, Tyler, I wanted to ask you for the benefit of people that aren't completely familiar or haven't heard it recently. You know, just the Genesis story for you. You were, you know, a your co-founder and VP of research now at Amazon, but you started with the other co-founders at UCLA. What was the aha moment where you knew you, you found something different. And then how did that lead into your collaboration here with Yannick? Sure. And you know, just before we get started, I can still remember when Yannick, actually one of his might have been his first meeting. We came and had a coffee at Sciences. Um, and I don't think we really knew each other very well back then. And so I was kind of like, ah, what are you talking about? Um, but, you know, eventually we figured out we spoke the same language. Um, and, and this is where we're at today. So. So my journey started. Um, I think there's some overlaps with what Yannick has been doing, actually. Uh, so I was a structural biologist. I was studying the way enzymes do the chemistry of life. Uh, I focused on those. Those enzymes that make natural products. These are used by bacteria for chemical warfare, to make the antibiotics and anti-cancer compounds that you use today tetracyclines, these different types of drugs, so on and so forth. That was great from a research perspective, but there was not really much applied science there. And so I moved to UCLA in 2008 to work on these more applied projects. It happened that that Jimbo. So this was the lab at UCLA who I joined, uh, didn't have an energy focused project. Uh, but they were getting money from the Doe. And so he figured I should have an energy related product project. And so pretty much built that, uh, that, that whole platform from the ground up. Uh, starting with an idea that Jim had, uh, to to provide alternatives to making biodiesel more efficiently, first with an enzyme solution and then with a engineered cell. Turns out engineering cells is really hard, as I think anybody who's familiar with that process will know. They're really complex. And literally the aha moment was Jim walking out of the door and saying, we just published this paper in a relatively high profile journal. This sucks. We need to change the way we do things. Let's go celebrate. And so, you know, it's interesting when scientists say things. Like, what are you when a scientist. Yeah. When he says that your boss does that and you go. I mean, is it just like, how do we do that? You look at it, you look at each other for a minute and you say, okay, like you're a -little crazy, but you. -Love the. -Mind. -But then you start thinking about it a little, you know? You you know, I could actually do this, and and it helps to be I mean, at the time I'm 45 now. This was 2012. So, you know, I was a little bit younger. Um, I was a little I was naive enough to think that it might be possible. And I had worked with these long pathways that are involved in we call it secondary metabolism because it's it's the same process that like your body's used to make fats and and energy, the bacteria just use a slightly modified version to make these natural product, these drugs. So I was very familiar with things that you would want to make, um, and how metabolism works. And I knew a lot about enzymes. And I was like, yeah, let's just try it. You know, I mean, these are the things these are the low hanging fruit, the easy things we could do very quickly. Um, and we just started building it out. Um, we kind of lucked into, uh, an early grant from the Department of Energy through Arpa e to develop turbines. Um, it was not just that it was a good idea, but the program manager also loves turbines. And so it helped that we -had a. -So what's a turbine for the for the -layman. What's a turbine. -So a turbine are those those chemicals in like lemons that give lemons like it makes lemons smell like a lemon? Uh, limonene is an example. Uh, perfumes, most of those are turbines or esters, but most of them are turbines. And so typically they're used as flavors and fragrances that uses attractants and plants. And so okay, I'm glad. I'm glad I asked because I was I was thinking turpentine. That was the first thing that came to mind. So that that is actually a compound as well. Okay. Um, and so you actually were not too far away. And the nice part is, is that, I mean, you can light turpentine on fire, right? And it burns. It's a hydrocarbon. And so you can, in theory, use these terpenes as fuels. And so that was why the Doe was interested in it. It's a relatively complex pathway. We built it out. And, you know, after we had published. So those were some of the publications Yannick was, was talking about. We had demonstrated that you could actually do all of these complex biosynthetic pathways. Cell three. And we were looking for what was the next thing, how could we apply it? Um, but we had demonstrated that it worked for Turpin and it worked for Isopentanol, which is the second gen biofuel. It works for bioplastics. Um, and so that was kind of where this started. But we were initially using just glucose like sugar that you bought from research grade. And part of the interest after we got to know a little bit better was he had access in all this knowledge to carbon feedstocks, how that supply chain actually works. What's the on on that side of it? You know, what are some of those technical and economic considerations that you have to think about if you're going to build a system that is eventually going to be commercial. In addition to his interest in other applications for cell free. Um, that could also touch the bio economy. So it was it was a really great you know, it took us a little -while, I think, to start working together. -But yeah. And I think that well, that's the other point. I think you said time, right? I mean, it took you guys time. I want to get into how you started working together, what you're working on, and then how that led to the to the grant. But I think for investors, it's important to understand that this isn't something I know. Although the company is new, newly founded and going to be newly public, that the technology and science and research behind that. Uh, again, like you said, I think believe it's 2008 that you started at UCLA working on this or at least 2000. 2008 to 2012. Yeah, right in that range. Yeah. So, I mean, we're talking 15 plus years and then Yannick and a team of 25 researchers working on their side of the equation in terms of deconstructing biomass into, you know, things that molecules that could be fuels, um, you know, has been going on for a decade plus as well. So how do these two, you know, enzyme following enzyme reactions to produce something? Uh, and the other line of science from bionics, how do you how did it to meet and what are you working on together specifically? Where did it start and then how did it lead to the grant? -Yeah. -So, you know, at first, you know, when I reached out to to Jim and Tyler was really beginning, it was really an exchange of enzymes, right? We were we just wanted to try a few things. And, uh, but like any collaborations, you know, it takes time to, to develop. And then you realize you have a lot of things in common, right? For example, we have a ton of experience with enzyme engineering and techno economic analysis. So knowing how things how much things cost when you're talking about making a fuel, commodity chemicals, that is something that people want to know, they're not going to pay $15 a gallon to power their car, right? Or even for, um, for jet fuel and so on. And same for the biomass. How much does it cost? How much can you get? Um, there's also lifecycle analysis. How much, how good is it for the planet and so on. And then and where we do a lot of things with separation as well. Right. So, so you know, we have, you know, we had a few projects before the game changer. Right. We had one that's just finishing up, that's um, called a uh, technology commercialization fund. And basically it's something that Doe has to connect to a company with annual so that you can develop, uh, technologies together. And basically it's made to, to enable like something that a technology that's almost to the point of being commercial, right. And really push it over that hurdle. Right. And so that helped us a lot to kind of see what we had in common, uh, identified areas that where Knoll could help. And, you know, so those areas are the ones I said before, like enzyme engineering and so on. That's what we did exactly in this particular project. But then we talked about what else could we do that would actually help in design because, you know, knowledge and love, that's what we want to do. We want to occupy that space between academia and industry, where we can basically kind of help, um, technologies get going. Right. And, and things are sometimes too risky for, for industry to actually fund internally. That's kind of what we specialize in. Right. And so we talked and. I think that's a that's an important point because I want to you know, people may see the face value of the of the game changer grants $250,000. You know, doesn't seem like a lot in technology development, especially in light of Invizyne. You know, they've had, I think, 13 plus million and other grant funding. But it's not about the monetary capital is what you're saying is really the intellectual capital and sharing of that that is is helping accelerate. Is that is that accurate and how do you do that? Right. Because I know part of the the focus is accelerating time to market. You mentioned it. How do we get Bridge the gap to commercialization and compress that. So how does that happen. So it happens first of all with a relationship and with an open sharing of both ideas and information. Uh, that is with the specific target in mind. Right. And so because we have this relationship beforehand, we knew what Emerald's capabilities were. We knew kind of how they thought about these problems. And then applying this for the game changer to accelerate the progression of butanol as a second generation fuel, you know, knowing like, what are the problem points that we are likely are these actual, um, difficulties? What how does it relate to the economics, the lifecycle analysis, all these different things? And then can we also use some of their capabilities on the separation side to potentially address some of these things? So that's kind of how it comes about in practice. How it actually happens is, you know, we have this active collaboration that has made the flow of information, I think, very easy and natural. Um, you know, we trust that, you know, Yannick and his group are really good at what they're doing. And, you know, I think they trust us that we're we're quite good at what we do. And so, you know, you can because you trust that what the information is, is true. Then it makes it that much easier to to push it forward. Um, to answer these questions. I don't know if that answers your. -Question, but. -Maybe you want to keep a different -perspective. Yeah. -No, I think it's. Yeah, I think you said that. You said it all. I think one thing we've really appreciated working with Invizyne over the years is that how much they're willing to share? Right. Of course, we have all the agreements in place and so on, because everything has to be protected. And of course, it should be. But Invizyne has been really good about, you know, compared to some other companies we work with in the past where it's not as fruitful because they just don't share as much. And so if we don't have all the information, we can't really give you all the answers that you need. I think Invisalign has been great at this. You know, if you're doing a technical economic analysis, you need all the information that they have internally, right? And for us, then we have the experience taking things from the benchtop to basically a pilot plant and an industry. Right. And well, has as a big pilot plant, we know how things will scale and so on. We can put those in the models. We know how separation will work when you have like 500 million gallon reactor, that's really different from just working at the bench, right? But for this to be useful, we need all the information we can get from the company. And I think Invizyne has been great at doing this. And I think it's why this collaboration is working so well. So the open exchange information, the the comparing of ideas. But then also what I'm hearing you say is, you know, you read in a press release that there's state of the art facilities, but give us some context. So you mentioned the 500. I couldn't catch it there. How big was the reactor like? So those in design have access to that through your collaboration. If you and your team obviously deem, hey, this is a resource that could be helpful in -accelerating this technology. -So those volumes where volumes you usually find in industry one things are, you know, going like full scale and so on. Um, and well, we have, you know, reactors in the pilot plant that I don't exactly remember how much, but 99,000l, for example. I think we have two of those. We can do fermentations, traditional ones, but we can also envision doing large self reactions or produce the enzymes that either would need. Um, gets a little complicated to know who has access to what. Usually, you know, there's a fee for service. Um, but of course, you know, we can write grants that would allow basically Invizyne to work with us to get access to it. Right. So I can't say it's free. Um, but because, you know, we have to get money in to do those projects, either the money comes from the company or it comes from a grant, basically, that we can write together. Um, but at least they have the access to the knowhow, right? Even if you don't use the reactor, there's a lot we know about how things will scale from one liter to 9000, 10,000 liter. Um, but I think ultimately, yes, we'd like. And it would be really nice for, uh, Invizyne to have access to that, because knowing how things scale at 10,000l, I think is usually where things start breaking, right, with microbes and so on. And so when people realize, oh, well, maybe the aeration is not good enough for the mixing is not what it should be at that scale, and so on. It's a lot. You realize what you start scaling your process. -Yeah. And I think that was. -Go ahead, go ahead. -I was going to say from your first. -Before title. -Go ahead. -It's all you. Some of the some of the early projects that we had, we're focused just on that. Right? The, the TCF project was using some of the infrastructure to solve some of the pain points that we had early on in terms of enzyme production and some of those logistics. So exactly what Yannick said, like that's how we view this, right, is how is it a win win for both design and roll and you know the bio -economy the nation generally. -So yeah. Yeah I thought I was just going to ask you I mean from your standpoint I mean obviously startup economy right. Startup company limited capital resources limited personnel resources. What does it mean to you and the team to have collaboration like this and access to the intellectual capital, the facilities, etc.. Like how can you contextualize that even even roughly like how fast that's helped move things along, or just what it's meant from, from the development of the company standpoint? Yeah, I mean, it's essential. I mean, as a start, as a, as a startup, you know, whose resources are limited. You gotta figure out what are the best ways, like, how do you get this stuff funded in the first instance? How do you keep it going? And then how do you do that as fast as possible, knowing that you have a limited amount of resources? So if you can use expertise and resources at NREL to help solve a problem that we have, then we should do that. And that only happens if you foster these relationships and you build them as well, because at the end of the day, we're we're, you know, people working together as well. And so, you know, the finance is part of it, but it's also kind of that trust. But like within that this has been an essential not just the grants, but also the work that we do within rail to push the status of, you know, production forward. So we can understand also moving forward, what are those pain points that we need to adjust in the next iteration as we get closer and closer to scale? Because that's just as equally important to know the earlier you know that the faster that process happens as well. So these come in the these come as like TS lke different types of aspects like that that inform that next generation of -built. -Yeah. No I mean look I think it's important for investors to hear and unsolicited, both of you talked about being commercial minded. How do you move things from the research to the application? Because I think the fear for investors normally is you get some really smart people pursuing research in a lot of directions, but there's no focus towards an end goal, right? And that's okay in an academic setting or a government research setting. But in a commercial setting where we're trying to, you know, bring a company to market, I think that's a fear. So I appreciate you kind of providing that perspective. Um, I want to kind of dive off of that a little bit to for you, Yanick. I mean, obviously you mentioned you have a team yourself, 25 people that work with you. You see a lot of different technologies or approaches and science help us. You know, from your view of the world, how does what Invizyne is doing? How could it be potentially a really big deal, like what's different? And why could this cell free approach really be a game changer to to be -cliche in that sense? -Yeah. I you know, I was going to say before you ask a question, you know, and that's all I have been there for 15 years, right, 15 years in that business. And the more I am there, the more I want to have an impact. Right? Because I see new technologies coming online. I see bio refineries coming online and closing and issues happening and so on. And, you know, a lot of things are related to, yes, the deconstruction of biomass, but also the grading and the fact that you don't get access to a lot of different products. And I think when I saw Cell Free and the, you know, early success from Tyler is really what can you do with it now you can get access to a product space basically that's not accessible with microbes or sometimes with chemical catalysis, because chemical catalysts will need high pressure, high temperature. It's sometimes it's tricky to do that. Microbes are just going to die if you make, you know, those all those molecules that you need to basically offset petroleum derived molecules, especially the ones that go into plastics, for example. So I think what, you know, Invizyne is working on, it is a game changer because it gets you access to those different, um, um, chemicals. And also when you talk about a bio or the bio economy as a whole, right, the fact that you have those enzymes that can produce, you know, products much quicker in smaller volumes and so on, you can think about the life cycle analysis. Do you have smaller ponds to treat your water? You have less power needed for, you know, sterilizing all your tanks and all this that you have with microbes. There's a lot of things that are basically good for the cost, but also the life cycle aspect of of your new bio economy. So I think it's it is a game changer in a lot of different respects. Yeah. So to just make sure I understand I mean you said originally it's the opening up new markets essentially, or new molecules that you could make that weren't available through the other approaches that you've seen. I mean, combined with doing traditional things more efficiently, more cost effective. -Because. -They're available to the other, you know, approaches, but it just would be more expensive. They would be not as good for for the environment, right? When you deal with high pressure, high temperatures to make all of those chemicals, even if they come from biomass, if you still have, if you still need a lot of heat and a lot of, you know, power generation to actually make them, it's still not good, right? So if you can find a way that 3D bio based, uh, low temperature, low pressure that can make all those interesting fuels and chemicals, I think this is this is a big deal. Yeah. Tyler, are you going to say something? I don't mean to cut you off. -Well, yeah, I agree. -That's good. Shortest answer today. Um, let me just kind of talk through. Just what are some milestones in the collaboration? Right. So investors always and tend to be milestone or inflection point driven. So for that standpoint what are things that you're looking at in the collaboration that would be, you know, staging gating items to move to the next phase or key accomplishments that would lead to commercialization. Just to help us understand what that might look like as this unfolds and the time associated -with that. -Yeah, I can take I can take the first step. So the initial milestones were to develop a. Very detailed techno techno economic analysis and to validate those TS that we had done internally, both on the enzyme production side and on the bio conversion side, from a variety of different sugar feedstocks into your your final product. So you get a very accurate idea using all of the data that NREL and the national Lab and all that information that they have accumulated over the years to basically, uh, refine those models that we had. So that's one one of the deliverables. Then also, -it's like a. -Feasibility, like with accurate data and say, hey, we think in theory, but now we have data that says this is -feasible. -That's right. Given, you know, XYZ assumptions in terms of productivity and how much you could make translating that then into a lifecycle analysis to figure out what's the actual carbon benefit at the end of the day? Um, that this process would because that's a very unique skill set and something that NREL is very, very good at. And on the third side, we know that one of the largest costs of, uh, ISO, you know, production from a bio based system is how well you can isolate it. And that heat, that energy costs us related to that. So can you develop new methods for that isolation of that chemical that are both efficient and cost effective from a cost and energy, uh, standpoint. So those are the three metrics that we were going after within this grant. Um, and I think we've made good progress towards those all -three. -Yeah. Now the professor is going -to grade you on that progress quickly. -I mean, game changer like financing that project was, you know, shale game changer, right? Was was I think was a big deal because it was kind of a first in terms of people have done those to models, LCA models, separations for everything you make with microbes, right? We sell three. It's kind of new except for Invizyne. Nobody had really done, you know, to of those processes. Right. And so being able to do that now it's it's a first off right. Say same for the separation every time I show you know, cell free based things, you know research and so on. At conferences people always ask me about the separation. How is it going to work with the enzymes? Are you going to keep the enzymes in there? Are you going to do separation as you're making your product? Is it an end thing? And all those things are important to figure out because they come into the cost, the lifecycle analysis and so on. So game changer, you know, financing this project. Um, I think we'll, we'll, we'll be really good for, for us to learn more and for the company as well. Um, when they go in front of the investors and say, look, those are numbers from, you know, nails to team is an internationally known basically they that's what they do. Um, that's a reference to the US or even in the world. So you can put that in front of, of people and say, yes, this is for real. Then I think that's that changes things. Yeah. It's kind of like peer reviewed research, right? I mean, this is third party validation and said, yeah, um, so what's the next steps? Right. You As you. Where does this go from here? And what other projects are you working on that can help investors know what what commercialization could look like is there, you know, is there a defined end time, uh, for the grant and what you're working on or. I know there's a lot of questions in there, so pick one. So maybe you can talk about the timeline in terms of like when this, uh, when the results are done and how we talk about that, and then I can talk about, uh, kind of what we think about what we think about -next. -Right? So, you know, in terms of timeline. So those projects, I can't remember exactly what, um, what was given to us at the beginning. Right. I think it's between usually between a year and two years. Um, we decided to do a year. We wanted a short timeline because those things we're working on are crucial for the for Invizyne. And so we decided to put a lot of efforts in directly. So I think we have probably another six months in the project. Um, I think the big milestones will be, uh, done by the end of August. Right. We'll have that that to that LCA model will have basically a list of, of separation technologies that could work and how do they scale and so on, how enzymes react to those. And all this. So I think we have six months, six more months to go. That's the end of this, um, project, um, as it is. But already there will be two big things will provide the company. Right. That will help them. And of course, after this, you know, we have plenty of other plans for going after different grants, right. Uh, another, um, one of those is the type of, of Doe funded research that I talked about, and that's really about getting those, um, those processes to market and so on. Um, but I'll let Tyler kind of elaborate on -this. -Yeah. And so the way that I look at it also is, you know, based off of some of these results, it'll allow us to say, okay, well, this actually might be a pain point, right? It could be that enzyme production and what hosts. And so this is something that we can work with NREL together through a TCF project to, to dial in further, uh, on top of what we've already done internally at Invizyne. Additionally, we can say, okay, well, these are the economics of this process. Actually, NREL already knows the economics of a different process that uses a different feedstock. We can actually use that feedstock potentially to upgrade into a different commodity chemical. And we have some proposals along those lines as well to continue to work on other aspects of chemicals that you can't get that would contribute to the bioeconomy. Um, that might be a little bit longer term. That's why we would work with them to develop those, uh, but still needs some of that fundamental knowledge, um, as well. So, you know, we can also take information that we have from our business development to say, okay, this is actually what the market is saying. These are products that could be useful. Um, you know, after you make us of, you know, because we already know that that that is a market driven need. Um, but there are, you know, molecules x, y, z that come off the back end of that, uh, that we can also -apply our research. -So, so it sounds like this is, you know, this collaboration started at least informally without the grants, uh, and should continue whether grants or not. Just because of what? what you're finding and the overlap. Which leads me to really the last question I always want to end on. Um, you know, for investors, we have opportunity costs, right? We have to make a choice, this investment or that investment. No different from my vantage point for researchers and scientists. You got to pick what area of expertise you're going to go down, what paths, what hypothesis you're going to test. Um, I guess my question to you, Yannick, to end and then we can go to, to to Tyler is you mentioned you decided at a certain point you wanted to have an impact. So what excites you? Like what's the from your perspective about designs, technologies that excites you about the impact it could have? And again, understanding this is your opinions based upon your background and not a guarantee of what's going to happen. So. Right. Well, you know, um, again, as I said earlier, I think with a lot of other technologies I've looked at, um, I've always felt like we're going to be limited to that one product that maybe then we need or that intermediate we need to upgrade athletically to something that would be directly usable, right? I think with the technology that Invizyne is developing, I can see that we can get to those products directly. We can get there with we can make a lot of them, make them fast. We can be carbon efficient. That's a big deal. Uh, because you guarantee the most. Well, most of your carbon, basically from your starting material, ends up in your, uh, in your product. And I think this this is a game changer as well. Um, because that's what you want, uh, for it to be basically a sustainable process, right? So I see basically access to a lot of, of molecules that usually are made with petroleum and that are hard to make with bio derived, uh, feedstocks and, and starting materials. So I think that's really what I'm excited about. And I can see that this will not only be beautiful, which is what this particular grant is about. It will be for countless chemicals that we need, um, maybe some of them to replace plastics as they are known now. Right. And be able to really recycle plastics, uh, instead of just, you know, sending them somewhere and pretending they recycle. So I think I see this as as really, um, um, a big deal. I'm really excited about excited about the next five, ten years of of the work that we'll be doing with Invisalign. See where they -are. -Yeah. And I think it's a great opportunity. But, you know, Yannick has a unique perspective in terms of the market and the state of the bio economy. You know what what things have benefit for replacing petroleum and what that, you know, effect might be on the environment. And when those align with what in designs core business model is right. These are the things that we also want to are already working on. And we can bring the self re expertise. And then and also has in addition to everything else that we've talked about, expertise and enzyme engineering and high throughput. And they can contribute in other ways as well. I think that that it just makes sense why we why wouldn't we continue to work together? Because it's in line with what we were both already doing. Um, and, you know, I think it's it's been a great relationship, um, both professionally and personally. And. Yeah, it's been great. Well, no, look, I think it's been extremely helpful because, you know, from the investment standpoint, as bankers, we always talk about platform technologies that can address multiple markets that are billions in scale. And I know that to some investors that those kind of pie in the sky statements just don't seem real or tangible. But so I appreciate you giving the on the ground real perspective on the research and saying like, hey, look, this is this is something now we have a grant that's accelerating towards ISO butanol. That's a potential, you know, $20 billion plus market, but then you can expand into other markets that really open up the full true potential of synthetic biology, which is what investors, you know, get attracted to. So, um, I want to leave it always last word with the two of you. Anything else? Any other comments you want to make about the technology, the collaboration, um, future predictions of who might win the white House. Now, we'll save that for a different cat. But, uh, gentlemen, I do. Floor is yours for the last, and then we'll we'll wrap. I just want to say, like, I think that being part of this show game changer has not just enabled us to the visibility and and the, the recognition that supported with it, but it's also a testament to to Yannick and his hard work and how good his team is. Uh, that shell has recognized NREL and what they can bring to the table and how that can push things forward as well. And, you know, we really, um, are thankful for this opportunity to be a part of it. And yeah, I mean, I know this is just part of how we work together, and I know we'll continue to work together -in the future. So thank you. -Yeah. And again, I wanted to yeah, I think game changer for, for um, you know, for this project. I think it personally for me it was a great experience as well. Right. Dealing with the company directly, um, seeing how we can help, uh, how we can have impact. Right. The research we do sometimes is fundamental. Just seeing how that translates. I think it's it's it was, um, a big deal for me. So, um, I'm happy to be part of it. Um, as I said, I'm looking to for many, many years of of sharing ideas with, uh, other and in design and, and again, seeing how we can have impact. Can we actually do something for this new bio economy? Right. And, um, and offset all of those, you know, petroleum derived products that we always make that, um, yeah, that has to stop at some point. So I think we're on the right track. Yeah. Well, listen, I want to thank you both. I always say that you can't fake sincerity, and it's clear that you both sincerely enjoy working with each other and the team, the collaboration. Um, I sincerely thank you for taking the time on a Friday in the middle of summer. So next time I'm actually in California or in the same spot, drinks are on me for the first round. Uh, as a as a small token of appreciation and and more than anything, I really appreciate you just giving perspective. Right. So this is as we look at the mosaic of how we consider the opportunity here for Invizyne. I know that for me, it's been helpful and hopefully for the rest of the audience, it'll be helpful for them to to grasp the science, the opportunity, and, you know, the importance of having someone like NREL and the validation that comes from that and the work and the, you know, the work that you've done your career too. So with that being said, thank you both. Enjoy the weekend and -we'll hopefully see each other soon. -All right. Thanks. Thanks. Yep.